What question did this study set out to answer?

The research aims to assess the effectiveness and tolerability of weekly RVD regimens in transplant-ineligible patients with newly diagnosed myeloma.

March 25, 2026Open Access

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Key Points

The research aims to assess the effectiveness and tolerability of weekly RVD regimens in transplant-ineligible patients with newly diagnosed myeloma.
Multicenter study conducted in Australia
Participants received weekly bortezomib, lenalidomide, and dexamethasone (RVD)
Outcomes measured included efficacy and toxicity
Weekly RVD regimens showed comparable efficacy to twice-weekly regimens
Toxicity levels remained a significant concern for patients

Abstract

This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Samantha Kurniawan

Angela Hwang

Nicole Wong Doo

Journals

Asia-Pacific Journal of Clinical Oncology

Actions

Institutions

The University of Sydney

UNSW Sydney

Royal Prince Alfred Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study